DK169765B1 - Serumfrit vækstmedium-additiv, koncentrat af dette, disses anvendelse ved kvalitetskontrol af fulde vækstmedier samt hydridomacellelinje til anvendelse hermed - Google Patents

Serumfrit vækstmedium-additiv, koncentrat af dette, disses anvendelse ved kvalitetskontrol af fulde vækstmedier samt hydridomacellelinje til anvendelse hermed Download PDF

Info

Publication number: DK169765B1
Authority: DK; Denmark
Prior art keywords: serum; growth medium; medium additive; free growth; edta
Prior art date: 1987-01-09

Application number

DK678687A

Other languages

Danish (da)

English (en)

Other versions

DK678687D0 (da

DK678687A (da

Inventor

Kjell Bertheussen

Original Assignee

Medi Cult As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-09

Filing date

1987-12-22

Publication date

1995-02-20

1987-12-22 Application filed by Medi Cult As filed Critical Medi Cult As

1987-12-22 Publication of DK678687D0 publication Critical patent/DK678687D0/da

1988-07-10 Publication of DK678687A publication Critical patent/DK678687A/da

1995-02-20 Application granted granted Critical

1995-02-20 Publication of DK169765B1 publication Critical patent/DK169765B1/da

Links

239000000654 additive Substances 0.000 title claims abstract description 33
230000000996 additive effect Effects 0.000 title claims abstract description 31
239000001963 growth medium Substances 0.000 title claims abstract description 26
239000012141 concentrate Substances 0.000 title claims description 7
238000003908 quality control method Methods 0.000 title 1
210000004027 cell Anatomy 0.000 claims abstract description 37
238000012360 testing method Methods 0.000 claims abstract description 18
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 17
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 15
210000004408 hybridoma Anatomy 0.000 claims abstract description 15
239000000203 mixture Substances 0.000 claims abstract description 12
229910052742 iron Inorganic materials 0.000 claims abstract description 8
239000011573 trace mineral Substances 0.000 claims abstract description 8
235000013619 trace mineral Nutrition 0.000 claims abstract description 8
GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims abstract description 5
210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 5
239000013522 chelant Substances 0.000 claims abstract description 5
210000004881 tumor cell Anatomy 0.000 claims abstract description 4
239000003102 growth factor Substances 0.000 claims abstract 2
230000010261 cell growth Effects 0.000 claims description 11
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
229910052751 metal Inorganic materials 0.000 claims description 8
239000002184 metal Substances 0.000 claims description 8
239000012980 RPMI-1640 medium Substances 0.000 claims description 7
238000004113 cell culture Methods 0.000 claims description 7
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
150000002739 metals Chemical class 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 claims description 4
239000000872 buffer Substances 0.000 claims description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
239000007995 HEPES buffer Substances 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
239000007640 basal medium Substances 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
229930182816 L-glutamine Natural products 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
-1 Na-pyruvate Chemical compound 0.000 claims 1
229910052783 alkali metal Inorganic materials 0.000 claims 1
150000001340 alkali metals Chemical class 0.000 claims 1
229910052782 aluminium Inorganic materials 0.000 claims 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
229910052804 chromium Inorganic materials 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
229910052748 manganese Inorganic materials 0.000 claims 1
229910052759 nickel Inorganic materials 0.000 claims 1
238000012372 quality testing Methods 0.000 abstract description 3
239000003513 alkali Substances 0.000 abstract 1
239000002609 medium Substances 0.000 description 23
210000002966 serum Anatomy 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 5
208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 5
230000012010 growth Effects 0.000 description 5
102000004338 Transferrin Human genes 0.000 description 4
108090000901 Transferrin Proteins 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
210000001161 mammalian embryo Anatomy 0.000 description 4
238000011160 research Methods 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
239000012581 transferrin Substances 0.000 description 4
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
231100000167 toxic agent Toxicity 0.000 description 3
239000003440 toxic substance Substances 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000017095 negative regulation of cell growth Effects 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001109 blastomere Anatomy 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000006790 cellular biosynthetic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
238000012136 culture method Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000010237 hybrid technique Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000797 iron chelating agent Substances 0.000 description 1
229940075525 iron chelating agent Drugs 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000006175 metal-ion buffer Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229910021654 trace metal Inorganic materials 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
150000003628 tricarboxylic acids Chemical class 0.000 description 1
229940072358 xylocaine Drugs 0.000 description 1
RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK678687A 1987-01-09 1987-12-22 Serumfrit vækstmedium-additiv, koncentrat af dette, disses anvendelse ved kvalitetskontrol af fulde vækstmedier samt hydridomacellelinje til anvendelse hermed DK169765B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NO870095A NO162160C (no)	1987-01-09	1987-01-09	Serumfritt vekstmedium, samt anvendelse derav.
NO870095		1987-01-09

Publications (3)

Publication Number	Publication Date
DK678687D0 DK678687D0 (da)	1987-12-22
DK678687A DK678687A (da)	1988-07-10
DK169765B1 true DK169765B1 (da)	1995-02-20

Family

ID=19889567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK678687A DK169765B1 (da)	1987-01-09	1987-12-22	Serumfrit vækstmedium-additiv, koncentrat af dette, disses anvendelse ved kvalitetskontrol af fulde vækstmedier samt hydridomacellelinje til anvendelse hermed

Country Status (16)

Country	Link
US (2)	US5045467A (pt)
EP (1)	EP0274445B1 (pt)
JP (2)	JPH0697996B2 (pt)
KR (1)	KR880009124A (pt)
AT (1)	ATE92098T1 (pt)
AU (1)	AU596491B2 (pt)
BR (1)	BR8800040A (pt)
CA (1)	CA1321961C (pt)
DE (1)	DE3882540T2 (pt)
DK (1)	DK169765B1 (pt)
ES (1)	ES2008411A6 (pt)
FI (1)	FI87230C (pt)
IL (1)	IL85026A (pt)
IT (1)	IT1215675B (pt)
NO (1)	NO162160C (pt)
NZ (1)	NZ223139A (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1307486C (en) *	1987-10-29	1992-09-15	Michael T. Largen	Hybridoma production
SE8801537D0 (sv) *	1988-04-26	1988-04-26	Ellco Food Ab	Cellodlingsmedium samt forfarande for dess framstellning
JPH03180175A (ja) *	1989-12-07	1991-08-06	Snow Brand Milk Prod Co Ltd	無血清培地
US5378612A (en) *	1990-05-11	1995-01-03	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Culture medium for production of recombinant protein
CA2111984A1 (en) *	1991-06-21	1993-01-07	Peter B. Suhr-Jessen	Iron chelate culture medium additive
GB9215834D0 (en) *	1992-07-24	1992-09-09	Celltech Ltd	Cell culture
DE4313620A1 (de) *	1993-04-26	1994-10-27	Biotechnolog Forschung Gmbh	Hamsterzellinien und Verfahren zur Glykoproteingewinnung
US5434185A (en) *	1993-05-17	1995-07-18	The University Of Kentucky Research Foundation	Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US5846529A (en) *	1993-08-23	1998-12-08	Nexell Therapeutics, Inc.	Infusion of neutrophil precursors for treatment of neutropenia
US6037174A (en) *	1993-08-23	2000-03-14	Nexell Therapeutics, Inc.	Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5395822A (en) *	1993-09-20	1995-03-07	Izumi; Yukitoshi	Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5593880A (en) *	1994-02-10	1997-01-14	Viratest International, Inc.	Dual-state nutritional medium for the transport and maintenance of cells
US5908782A (en) *	1995-06-05	1999-06-01	Osiris Therapeutics, Inc.	Chemically defined medium for human mesenchymal stem cells
WO1997033978A1 (en)	1996-03-12	1997-09-18	Life Technologies, Inc.	Hematopoietic cell culture nutrient supplement
US6043092A (en) *	1996-03-18	2000-03-28	University Of Pittsburgh	Cell culture media for mammalian cells
US6511848B2 (en) *	1996-04-17	2003-01-28	Winfried Albert	Process for producing and multiplying lymphocytes
JP2000517188A (ja)	1996-08-30	2000-12-26	ライフテクノロジーズ，インコーポレイテッド	無血清哺乳動物細胞培養培地およびその使用
US6833271B2 (en) *	1996-12-04	2004-12-21	Medi-Cult A/S	Serum-free cell culture media
GB9625175D0 (en) *	1996-12-04	1997-01-22	Medi Cult As	Serum-free cell culture media
US5804420A (en) *	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
AU2878200A (en) *	1999-02-11	2000-08-29	Schepens Eye Research Institute, Inc., The	Growth medium for human corneal endothelial cells
US6767741B1 (en) *	1999-08-27	2004-07-27	Invitrogen Corporation	Metal binding compounds and their use in cell culture medium compositions
DE60037819T2 (de) *	1999-08-27	2009-01-08	Invitrogen Corp., Carlsbad	Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
GB0003231D0 (en) *	2000-02-11	2000-04-05	Medi Cult As	Cell culture media
US20030096414A1 (en) *	2001-03-27	2003-05-22	Invitrogen Corporation	Culture medium for cell growth and transfection
WO2002099089A1 (en) *	2001-06-04	2002-12-12	Corixa Corporation	Compositions and methods for high-level, large-scale production of recombinant proteins
US7087369B2 (en) *	2003-12-17	2006-08-08	The Regents Of The University Of California	Cornea preservation medium
US20080085298A1 (en) *	2004-03-12	2008-04-10	Biodel, Inc.	Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) *	2004-03-12	2008-04-24	Biodel, Inc.	Rapid mucosal gel or film insulin compositions
US8273553B2 (en)	2004-11-02	2012-09-25	Ares Trading S.A.	Production of growth hormone in serum-free cell culture medium for mammalian cells
DE602005026548D1 (de)	2004-11-02	2011-04-07	Ares Trading Sa	Serumfreies kulturmedium für säugerzellen
AU2005322353B2 (en)	2004-12-23	2011-09-01	Medimmune, Llc	Non-tumorigenic MDCK cell line for propagating viruses
RS57549B1 (sr)	2005-08-26	2018-10-31	Ares Trading Sa	Proces za pripremu glikoziliranog interferona beta
JP4385076B2 (ja)	2006-01-13	2009-12-16	独立行政法人科学技術振興機構	動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用
EP2495307B9 (en) *	2006-07-13	2018-05-02	Wyeth LLC	Production of coagulation factor IX with improved glycosylation pattern
EP2615167A1 (en)	2006-09-15	2013-07-17	MedImmune, LLC	Method for eliminating DNA contaminants from viral preparations
US8361741B2 (en)	2007-08-29	2013-01-29	Millipore Corporation	Serum-free growth medium for Acholeplasma laidlawii and methods for retention testing sterilizing grade filters
CN102215865B (zh)	2008-09-24	2013-10-30	米迪缪尼有限公司	病毒纯化方法
KR101712501B1 (ko) *	2008-11-11	2017-03-07	고쿠리츠다이가쿠호진 히로시마다이가쿠	분화 유도 배지용 첨가제 및 그의 용도
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
DK2545928T3 (en)	2010-03-10	2016-10-03	Two Cells Co Ltd	CELL PREPARATION CONTAINING MESENYKYMAL STEM CELLS AND METHOD OF PRODUCING THEREOF
CA3051089C (en)	2012-05-02	2022-04-12	Life Technologies Corporation	High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2015143512A2 (en) *	2014-03-23	2015-10-01	Advantech Bioscience Farmacêutica Ltda.	Enhancement of recombinant protein expression with copper
AR102869A1 (es)	2014-12-16	2017-03-29	Lilly Co Eli	Composiciones de insulina de rápida acción
US10119117B2 (en)	2016-01-28	2018-11-06	Nanogen Pharmaceutical Biotechnology Co., Ltd	Universal, glycosylation enhancer, completely chemically defined medium formulation
SG11201908891YA (en) *	2017-03-31	2019-10-30	Boehringer Ingelheim Int	Perfusion medium
CN110835622B (zh) *	2018-08-16	2021-04-27	上海药明生物技术有限公司	用于调节哺乳动物细胞乳酸代谢的培养基及其应用
WO2025033487A1 (ja) *	2023-08-09	2025-02-13	国立研究開発法人産業技術総合研究所	血清または血清代替物の品質管理方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4466917A (en) *	1981-02-12	1984-08-21	New York University	Malaria vaccine
US4544632A (en) *	1981-06-12	1985-10-01	Yuichi Yamamura	Human T cell lines and method of producing same
IL74298A (en) *	1982-05-13	1985-09-29	Israel State	Material obtainable from"green islands"for the prevention of virus replication in plants,its isolation and its use for plant immunization
US4604284A (en) *	1983-09-20	1986-08-05	Hoffmann-La Roche Inc.	Homogeneous immune interferon fragment
EP0156169B1 (en) *	1984-02-29	1991-12-18	Asahi Kasei Kogyo Kabushiki Kaisha	An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
JPS6158584A (ja) *	1984-08-30	1986-03-25	Ube Ind Ltd	細胞増殖促進剤及び細胞増殖促進方法
JP2967117B2 (ja) *	1989-03-14	1999-10-25	旭化成工業株式会社	電子線硬化型導電性ペースト組成物

1987
- 1987-01-09 NO NO870095A patent/NO162160C/no not_active IP Right Cessation
- 1987-12-22 DK DK678687A patent/DK169765B1/da not_active IP Right Cessation
- 1987-12-24 KR KR1019870014892A patent/KR880009124A/ko not_active Ceased
- 1987-12-31 FI FI875793A patent/FI87230C/fi not_active IP Right Cessation
1988
- 1988-01-05 IL IL8502688A patent/IL85026A/xx not_active IP Right Cessation
- 1988-01-07 AU AU10115/88A patent/AU596491B2/en not_active Ceased
- 1988-01-07 BR BR8800040A patent/BR8800040A/pt not_active IP Right Cessation
- 1988-01-08 ES ES8800030A patent/ES2008411A6/es not_active Expired
- 1988-01-08 JP JP236888A patent/JPH0697996B2/ja not_active Expired - Fee Related
- 1988-01-08 CA CA 556106 patent/CA1321961C/en not_active Expired - Fee Related
- 1988-01-08 NZ NZ22313988A patent/NZ223139A/xx unknown
- 1988-01-08 IT IT1902488A patent/IT1215675B/it active
- 1988-01-08 DE DE88300121T patent/DE3882540T2/de not_active Expired - Lifetime
- 1988-01-08 AT AT88300121T patent/ATE92098T1/de not_active IP Right Cessation
- 1988-01-08 EP EP19880300121 patent/EP0274445B1/en not_active Expired - Lifetime
- 1988-01-11 US US07/142,069 patent/US5045467A/en not_active Expired - Lifetime
1990
- 1990-02-23 US US07/484,557 patent/US5045454A/en not_active Expired - Lifetime
1994
- 1994-02-28 JP JP5256094A patent/JP2524313B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IT1215675B (it)	1990-02-22
NZ223139A (en)	1991-09-25
CA1321961C (en)	1993-09-07
KR880009124A (ko)	1988-09-14
NO870095L (no)	1988-07-11
DE3882540T2 (de)	1993-11-18
BR8800040A (pt)	1988-08-02
ES2008411A6 (es)	1989-07-16
US5045454A (en)	1991-09-03
DE3882540D1 (de)	1993-09-02
JPS63279786A (ja)	1988-11-16
NO162160B (no)	1989-08-07
JPH0697996B2 (ja)	1994-12-07
EP0274445A2 (en)	1988-07-13
FI87230B (fi)	1992-08-31
ATE92098T1 (de)	1993-08-15
DK678687D0 (da)	1987-12-22
JP2524313B2 (ja)	1996-08-14
JPH06292570A (ja)	1994-10-21
DK678687A (da)	1988-07-10
FI875793A0 (fi)	1987-12-31
EP0274445A3 (en)	1989-12-13
AU1011588A (en)	1988-07-14
IL85026A (en)	1992-09-06
FI875793L (fi)	1988-07-10
EP0274445B1 (en)	1993-07-28
AU596491B2 (en)	1990-05-03
US5045467A (en)	1991-09-03
NO870095D0 (no)	1987-01-09
NO162160C (no)	1989-11-15
IL85026A0 (en)	1988-06-30
IT8819024A0 (it)	1988-01-08
FI87230C (fi)	1992-12-10

Publication	Publication Date	Title
DK169765B1 (da)	1995-02-20	Serumfrit vækstmedium-additiv, koncentrat af dette, disses anvendelse ved kvalitetskontrol af fulde vækstmedier samt hydridomacellelinje til anvendelse hermed
McCarthy et al.	1983	1, 25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells
Moore et al.	1973	Cytogenetic analysis of human acute and chronic myeloid leukemic cells cloned in agar culture
Eliason et al.	1979	Erythropoietin-stimulated erythropoiesis in long-term bone marrow culture
EP1210410B1 (en)	2008-01-16	Metal binding compounds and their use in cell culture medium compositions
Chaleff	1982	Induction, maintenance, and differentiation of rice callus cultures on ammonium as sole nitrogen source
CN115786269A (zh)	2023-03-14	一种胎盘类器官模型的构建方法
EP0593539A1 (en)	1994-04-27	Iron chelate culture medium additive
Abrahams et al.	1968	Assessment of viability of frozen bone marrow cells using a cell‐culture method
Schlunk et al.	1981	Survival of human bone marrow progenitor cells after freezing: Improved detection in the colony-formation assay
Singh et al.	1975	Effects of different 2, 4-D concentrations on the cytogenetic behaviour of plant cells cultured in vitro
Dubin et al.	1965	Effects of albumin fraction and linoleic acid on growth of macrophages in tissue culture
Martı́nez-Poveda et al.	2003	An in vitro evaluation of the effects of homocysteine thiolactone on key steps of angiogenesis and tumor invasion
Stopp et al.	1980	In vitro analysis of drug-induced stimulation of renal tubular p-aminohippurate (PAH) transport in rats
Liang et al.	2021	Amniotic fluid transplantation alleviates hematopoietic deficits in experimental rat aplastic anemia
Sato et al.	1989	Stimulation of monoclonal antibody production by human-human hybridoma cells with an elevated concentration of potassium or sodium phosphate in serum-free medium
CN114377013B (zh)	2023-12-19	去甲波尔定的应用及其促进间充质干细胞向成骨细胞分化的方法
Tsiftsoglou et al.	1979	Dimethyl sulfoxide-induced differentiation of Friend erythroleukemia cells in the absence of cytokinesis
Petersen et al.	1974	Kinetics of rat bone marrow cells cultured in diffusion chambers: effect of heterologous implantation and irradiation of the host
Sheridan et al.	1984	Potentiation of anchorage-independent colony formation by sodium polyanethol sulphonate
Connelly	1980	The influence of hormones and other substances on lens regeneration in vitro
Donta	1975	Growth of functional glial cells in a serumless medium
Chan et al.	1991	Diadenosine tetraphosphate (Ap4A) and triphosphate (Ap3A) signaling of human sperm motility
KR880002318B1 (ko)	1988-10-22	무혈청 배지
Herrmann et al.	1995	Cytogenetic analysis of thyroid tumors after cryopreservation

Legal Events

Date	Code	Title	Description
1995-02-20	B1	Patent granted (law 1993)
2008-01-14	PUP	Patent expired